




Uni-Bio Science covers the entire biotech value chain




International senior management team



BOD with extensive industry experience





Vision The global Chinese healthcare partner for innovative treatments

Mission Improve healthcare through innovative science

About Us

Uni-Bio Science Group is a Chinese biopharmaceutical company engaged in the research, development, production and commercialization of pharmaceuticals for the Chinese healthcare market via four of its wholly owned subsidiaries. The Group is focused on addressing high unmet medical needs in diseases such as diabetes, ophthalmology and dermatology through the development and commercialization of novel therapies. Led by a highly experienced management team and Board of Directors with broad international pharmaceutical and commercial experience, Uni-Bio Science Group was founded in 2001 and is listed on the Hong Kong Stock Exchange (Stock Code: 0690).

Winner of The Best IR Company - Small Cap

Among 1800 HKSE listed companies, Uni-Bio Science was elected as one of the nominees for "The Best IR Company - Small Cap" in 2015 alongside 30 renowned companies. Under fierce competition and careful consideration by professional judges, Uni-Bio Science was ultimately crowned the winner.



Three marketed products with outstanding growth

GeneTime®

- EGF Spray
- Biologic
- Indicated for wound healing



Listed on NRDL



GeneSoft®

- EGF Ophthalmic Solution
- Biologic
- Indicated for corneal wound treatment



Targeting NRDL listing



Pinapu®

- Voriconazole
- Chemical
- Fungal infection treatment



Listed on NRDL



Innovative pipeline - two potential blockbuster launches in 2017

Uni-pTH

Recombinant Parathyroid Hormone 1-34 (biologic)



- Targets serious osteoporosis
- Capable of increasing bone mass density
- Relives bone pain



China accounts for

37%

of global osteoporosis population



China market expected to reach

HKD19.5B

in 2015



Potentially the

First

domestic company to launch

Uni-E4

Recombinant Exendin-4 (biologic)



- Type II diabetes treatment
- A class of drug leading to weight loss
- Lower risk of hypoglycemia
- Promotes β -cell regeneration



China patient population exceeded

100M



China market expected to reach

HKD25B

in 2016



Potentially the

First

domestic company to launch